{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:57:20Z","timestamp":1767992240097,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T00:00:00Z","timestamp":1541116800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"ABREOC 2016"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1038\/s41409-018-0379-y","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T15:19:47Z","timestamp":1541171987000},"page":"1029-1037","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Melphalan dose in myeloma patients \u226565 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study"],"prefix":"10.1038","volume":"54","author":[{"name":"On behalf of the Swiss Blood Stem Cell Transplantation Registry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Ghilardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Jeker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rouven","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Cairoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia M. S.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Bargetzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicitas","family":"Hitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Baldomero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Heim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Ghielmini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Wannesson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Lerch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Samaras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urs","family":"Schanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob R.","family":"Passweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Stussi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2433-4753","authenticated-orcid":false,"given":"Martina","family":"Kleber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,2]]},"reference":[{"key":"379_CR1","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875\u201383. \n                    https:\/\/doi.org\/10.1056\/NEJMoa022340","journal-title":"N Engl J Med"},{"key":"379_CR2","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","volume":"371","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:895\u2013905. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1402888","journal-title":"N Engl J Med"},{"key":"379_CR3","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311\u201320. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1611750","journal-title":"N Engl J Med"},{"key":"379_CR4","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863\u20139. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.61.2267","journal-title":"J Clin Oncol"},{"key":"379_CR5","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1182\/blood-2009-09-241737","volume":"115","author":"A Palumbo","year":"2010","unstructured":"Palumbo A, Bringhen S, Bruno B, Falcone AP, Liberati AM, Grasso M, et al. Melphalan 200 mg\/m(2) versus melphalan 100 mg\/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood. 2010;115:1873\u20139. \n                    https:\/\/doi.org\/10.1182\/blood-2009-09-241737","journal-title":"Blood"},{"key":"379_CR6","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"P Moreau","year":"2002","unstructured":"Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, et al. Comparison of 200 mg\/m(2) melphalan and 8 Gy total body irradiation plus 140 mg\/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002;99:731\u20135.","journal-title":"Blood"},{"key":"379_CR7","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/sj.bmt.1705514","volume":"38","author":"E Jantunen","year":"2006","unstructured":"Jantunen E. Autologous stem cell transplantation beyond 60 years of age. Bone Marrow Transplant. 2006;38:715\u201320. \n                    https:\/\/doi.org\/10.1038\/sj.bmt.1705514","journal-title":"Bone Marrow Transplant"},{"key":"379_CR8","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1200\/JCO.2014.55.1028","volume":"32","author":"TM Wildes","year":"2014","unstructured":"Wildes TM, Rosko A, Tuchman SA. Multiple myeloma in the older adult: better prospects, more challenges. J Clin Oncol. 2014;32:2531\u201340. \n                    https:\/\/doi.org\/10.1200\/JCO.2014.55.1028","journal-title":"J Clin Oncol"},{"key":"379_CR9","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1046\/j.1365-2141.2001.02976.x","volume":"114","author":"A Badros","year":"2001","unstructured":"Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol. 2001;114:600\u20137.","journal-title":"Br J Haematol"},{"key":"379_CR10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/sj.bmt.1705627","volume":"39","author":"MA Gertz","year":"2007","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Leung N, et al. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. 2007;39:605\u201311. \n                    https:\/\/doi.org\/10.1038\/sj.bmt.1705627","journal-title":"Bone Marrow Transplant"},{"key":"379_CR11","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/sj.bmt.1705360","volume":"37","author":"E Jantunen","year":"2006","unstructured":"Jantunen E, Kuittinen T, Penttila K, Lehtonen P, Mahlamaki E, Nousiainen T. High-dose melphalan (200 mg\/m2) supported by autologous stem cell transplantation is safe and effective in elderly (> or =65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant. 2006;37:917\u201322. \n                    https:\/\/doi.org\/10.1038\/sj.bmt.1705360","journal-title":"Bone Marrow Transplant"},{"key":"379_CR12","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","volume":"104","author":"A Palumbo","year":"2004","unstructured":"Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood. 2004;104:3052\u20137. \n                    https:\/\/doi.org\/10.1182\/blood-2004-02-0408","journal-title":"Blood"},{"key":"379_CR13","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","volume":"370","author":"T Facon","year":"2007","unstructured":"Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370:1209\u201318. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(07)61537-2","journal-title":"Lancet"},{"key":"379_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/bmt.2014.255","volume":"50","author":"HW Auner","year":"2015","unstructured":"Auner HW, Szydlo R, Hoek J, Goldschmidt H, Stoppa AM, Morgan GJ, et al. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplant. 2015;50:209\u201315. \n                    https:\/\/doi.org\/10.1038\/bmt.2014.255","journal-title":"Bone Marrow Transplant"},{"key":"379_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000357394","volume":"132","author":"S Ozaki","year":"2014","unstructured":"Ozaki S, Harada T, Saitoh T, Shimazaki C, Itagaki M, Asaoku H, et al. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network. Acta Haematol. 2014;132:211\u20139. \n                    https:\/\/doi.org\/10.1159\/000357394","journal-title":"Acta Haematol"},{"key":"379_CR16","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1016\/j.bbmt.2014.07.013","volume":"20","author":"M Sharma","year":"2014","unstructured":"Sharma M, Zhang MJ, Zhong X, Abidi MH, Akpek G, Bacher U, et al. Older patients with myeloma derive similar benefit from autologous transplantation. Biol Blood Marrow Transplant. 2014;20:1796\u2013803. \n                    https:\/\/doi.org\/10.1016\/j.bbmt.2014.07.013","journal-title":"Biol Blood Marrow Transplant"},{"key":"379_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/bjh.13608","volume":"171","author":"HW Auner","year":"2015","unstructured":"Auner HW, Garderet L, Kroger N. Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma. Br J Haematol. 2015;171:453\u201362. \n                    https:\/\/doi.org\/10.1111\/bjh.13608","journal-title":"Br J Haematol"},{"key":"379_CR18","first-page":"508","volume":"85","author":"A Palumbo","year":"2000","unstructured":"Palumbo A, Triolo S, Baldini L, Callea V, Capaldi A, De Stefano V, et al. Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients. Haematologica. 2000;85:508\u201313.","journal-title":"Haematologica"},{"key":"379_CR19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V93.1.51","volume":"93","author":"DS Siegel","year":"1999","unstructured":"Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood. 1999;93:51\u201354.","journal-title":"Blood"},{"key":"379_CR20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/sj.bmt.1702188","volume":"25","author":"B Sirohi","year":"2000","unstructured":"Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H, et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant. 2000;25:533\u20139. \n                    https:\/\/doi.org\/10.1038\/sj.bmt.1702188","journal-title":"Bone Marrow Transplant"},{"key":"379_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/annonc\/mdt509","volume":"25","author":"M Merz","year":"2014","unstructured":"Merz M, Neben K, Raab MS, Sauer S, Egerer G, Hundemer M, et al. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents. Ann Oncol. 2014;25:189\u201395. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdt509","journal-title":"Ann Oncol"},{"key":"379_CR22","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/bmt.2015.106","volume":"50","author":"TM Wildes","year":"2015","unstructured":"Wildes TM, Finney JD, Fiala M, Gao F, Vij R, Stockerl-Goldstein K, et al. High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma. Bone Marrow Transplant. 2015;50:1075\u201382. \n                    https:\/\/doi.org\/10.1038\/bmt.2015.106","journal-title":"Bone Marrow Transplant"},{"key":"379_CR23","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412\u201320. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.04.242","journal-title":"J Clin Oncol"},{"key":"379_CR24","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467\u201373. \n                    https:\/\/doi.org\/10.1038\/sj.leu.2404284","journal-title":"Leukemia"},{"key":"379_CR25","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"key":"379_CR26","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.3324\/haematol.2016.150334","volume":"101","author":"L Garderet","year":"2016","unstructured":"Garderet L, Beohou E, Caillot D, Stoppa AM, Touzeau C, Chretien ML, et al. Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study. Haematologica. 2016;101:1390\u20137. \n                    https:\/\/doi.org\/10.3324\/haematol.2016.150334","journal-title":"Haematologica"},{"key":"379_CR27","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3324\/haematol.2017.181339","volume":"103","author":"HW Auner","year":"2018","unstructured":"Auner HW, Iacobelli S, Sbianchi G, Knol-Bout C, Blaise D, Russell NH, et al. Melphalan 140 mg\/m(2) or 200 mg\/m(2) for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. Haematologica. 2018;103:514\u201321. \n                    https:\/\/doi.org\/10.3324\/haematol.2017.181339","journal-title":"Haematologica"},{"key":"379_CR28","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"349","author":"M Attal","year":"2003","unstructured":"Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495\u2013502. \n                    https:\/\/doi.org\/10.1056\/NEJMoa032290","journal-title":"N Engl J Med"},{"key":"379_CR29","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","volume":"117","author":"M Cavo","year":"2011","unstructured":"Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Blade J, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117:6063\u201373. \n                    https:\/\/doi.org\/10.1182\/blood-2011-02-297325","journal-title":"Blood"},{"key":"379_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2011.34","volume":"1","author":"M Kleber","year":"2011","unstructured":"Kleber M, Ihorst G, Terhorst M, Koch B, Deschler B, Wasch R, et al. Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J. 2011;1:e35 \n                    https:\/\/doi.org\/10.1038\/bcj.2011.34","journal-title":"Blood Cancer J"},{"key":"379_CR31","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125:2068\u201374. \n                    https:\/\/doi.org\/10.1182\/blood-2014-12-615187","journal-title":"Blood"},{"key":"379_CR32","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3324\/haematol.2016.162693","volume":"102","author":"M Engelhardt","year":"2017","unstructured":"Engelhardt M, Domm AS, Dold SM, Ihorst G, Reinhardt H, Zober A, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102:910\u201321. \n                    https:\/\/doi.org\/10.3324\/haematol.2016.162693","journal-title":"Haematologica"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0379-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0379-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0379-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:13:26Z","timestamp":1684617206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-018-0379-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,2]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["379"],"URL":"https:\/\/doi.org\/10.1038\/s41409-018-0379-y","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,2]]},"assertion":[{"value":"8 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}